Nalaganje...

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer

Immune checkpoint inhibitors radically changed the treatment of patients with non-small cell lung cancer (NSCLC). However, only one-quarter of patients benefit from these new therapies when used as monotherapy. The assessment of Program Death Ligand-1 (PD-L1) tumor expression by immunohistochemistry...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancers (Basel)
Main Authors: Kaderbhaï, Courèche, Tharin, Zoé, Ghiringhelli, François
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2019
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6406957/
https://ncbi.nlm.nih.gov/pubmed/30744168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11020201
Oznake: Označite
Brez oznak, prvi označite!